271 related articles for article (PubMed ID: 37592723)
1. Emerging pharmacological strategies for treating and preventing mpox.
Grosenbach DW; Russo AT; Blum ED; Hruby DE
Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
[TBL] [Abstract][Full Text] [Related]
2. Treatment and Vaccination for Smallpox and Monkeypox.
Saalbach KP
Adv Exp Med Biol; 2024; 1451():301-316. PubMed ID: 38801586
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
[TBL] [Abstract][Full Text] [Related]
5. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
[TBL] [Abstract][Full Text] [Related]
6. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
8. A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus.
Chenchula S; Ghanta MK; Amerneni KC; Rajakarunakaran P; Chandra MB; Chavan M; Gupta R
Arch Virol; 2023 Jun; 168(7):195. PubMed ID: 37386209
[TBL] [Abstract][Full Text] [Related]
9. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
11. The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?
Ezat AA; Abduljalil JM; Elghareib AM; Samir A; Elfiky AA
Expert Opin Drug Discov; 2023 May; 18(5):551-561. PubMed ID: 37032577
[TBL] [Abstract][Full Text] [Related]
12. Mpox (monkeypox): Diagnosis, prevention, and management in adults.
Jarrell L; Perryman K
Nurse Pract; 2023 Apr; 48(4):13-20. PubMed ID: 36975744
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
14. Mpox: Rapid Evidence Review.
Saguil A; Krebs L; Choe U
Am Fam Physician; 2023 Jul; 108(1):78-83. PubMed ID: 37440743
[TBL] [Abstract][Full Text] [Related]
15. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult.
Dammann F; Raja M; Camargo JF
Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983
[TBL] [Abstract][Full Text] [Related]
16. Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.
Bruno G; Buccoliero GB
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895350
[TBL] [Abstract][Full Text] [Related]
17. Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements.
Rani I; Joshi H; Sharma U; Kaur J; Sood S; Ramniwas S; Chauhan A; Abdulabbas HS; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2055-2065. PubMed ID: 37837475
[TBL] [Abstract][Full Text] [Related]
18. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Prevention and Management of Monkeypox Viral Infection in Humans.
Gujjar P; Chaudhay R; Verma I; Bansal N; Gupta S; Bansal S
Curr Drug Targets; 2023; 24(13):1032-1045. PubMed ID: 37842888
[TBL] [Abstract][Full Text] [Related]
20. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Siegrist EA; Sassine J
Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
